Abstract 458P
Background
Communication is a complex process; an effective communication requires a two-way relationship between patients (pts) and healthcare providers (hp). The areas of communication concern diagnosis, prognosis and treatment. In this context, a tailored communication approach is suggested to keep pts involved in the clinical decision-making process.
Methods
Between 21 June and 4 October 2022, a 38-question web survey, promoted by the IncontraDonna Foundation and carried out in collaboration with both the Italian Society of Psycho-Oncology (SIPO) and the Italian Association of Medical Oncology (AIOM), was sent to oncologists members of AIOM. The aim of this study was both to investigate how and how much oncologists communicate with metastatic breast cancer pts (mBCp) and to probe clinicians’ opinions and needs.
Results
140 oncologists from 19 Italian regions participated in the survey. Responders reported discussing prognosis with their mBCp both in terms of residual life (96%), goals of care (98%) and likelihood of treatment response (94%), in the last two cases especially at the time of the first oncological visit (67% and 60%, respectively). As many as 93% of responders stated that they investigate the degree of understanding of the information provided. In communicating the prognosis, 49% of responders considered the presence of a caregiver "very useful” and 61% considered her/his absence "very disadvantageous". About the organization of one's department, the time dedicated to doctor-patient communication was considered "quite sufficient” in 16%", "little but sufficient” in 44%, "scarce” in 31% and "insufficient ” in 10% of cases. In 89% of cases the presence of a psycho-oncology service was reported, to which mBCp would be referred regularly in only 14% of cases. Specific training courses for hp (69%) and periodic meetings with expert psycho-oncologists (59%) are the improvement actions most requested by clinicians.
Conclusions
The results of this survey highlighted heterogeneity in the management of communication in mBCp across the Italian country. Although the figure of the psycho-oncologist is considered important, its integration into the therapeutic process still appears complex.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Gerratana: Financial Interests, Personal, Advisory Role: AstraZeneca, Daiichi Sankyo, Eli Lilly, GSK, Incyte, Novartis, Pfizer. S. Spazzapan: Financial Interests, Personal, Advisory Board: MSD Italia, Seagen, AstraZeneca; Financial Interests, Personal, Invited Speaker: MSD, Novartis, Mundipharma, AstraZeneca, Eli Lilly; Financial Interests, Personal, Other, Congress registration: Pfizer; Financial Interests, Personal, Other, Tutoring: AstraZeneca; Financial Interests, Personal, Other, congress registration and travel expenses: Pfizer; Financial Interests, Personal, Other, Congress registration and travel expenses: Novartis; Financial Interests, Institutional, Local PI: AstraZeneca. S. Cinieri: Other, Personal, Member of Board of Directors, President: AIOM. F. Puglisi: Financial Interests, Personal and Institutional, Funding, Personal fees: AstraZeneca; Financial Interests, Institutional, Funding: Eisai; Financial Interests, Personal, Other, Personal fees: Roche, Amgen, Eli Lilly, Novartis, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
467P - Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
Presenter: Isaac Ceballos Lenza
Session: Poster session 04
468P - Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study
Presenter: Eda Caliskan Yildirim
Session: Poster session 04
469P - Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment
Presenter: Maria Torrente
Session: Poster session 04
470P - Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Presenter: Marco Bergamini
Session: Poster session 04
471P - Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
Presenter: Chiara Paratore
Session: Poster session 04
472P - Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
Presenter: Joshua Tobias
Session: Poster session 04
473P - Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
Presenter: Kreina Vega Cano
Session: Poster session 04
474P - ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
Presenter: Aaron Lin
Session: Poster session 04
475P - Dynamics of TROP2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04
478P - Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
Presenter: Antonella Palazzo
Session: Poster session 04